Literature DB >> 29114991

Serum autotaxin is a useful liver fibrosis marker in patients with chronic hepatitis B virus infection.

Satoru Joshita1,2, Yuki Ichikawa1, Takeji Umemura1,2, Yoko Usami3, Ayumi Sugiura1, Soichiro Shibata1, Tomoo Yamazaki1, Naoyuki Fujimori1, Michiharu Komatsu1, Akihiro Matsumoto1, Koji Igarashi4, Masao Ota1, Eiji Tanaka1.   

Abstract

AIM: Autotaxin (ATX) is a secreted enzyme that is considered to be associated with liver damage as well as fibrosis. This study assessed the ability of ATX to diagnose liver fibrosis in patients with chronic hepatitis B virus (HBV) infection.
METHODS: Serum ATX levels were retrospectively evaluated in 101 treatment-naïve patients with HBV-related chronic hepatitis or cirrhosis, all of whom had undergone liver biopsy at our hospital.
RESULTS: Serum ATX concentration increased significantly according to liver fibrosis stage in overall (r = 0.46, P < 0.0001), male (r = 0.55, P < 0.0001), and female (r = 0.52, P = 0.0006) patient groups. When analyzed by gender, serum ATX was one of the most reliable markers for all fibrosis stages compared with other tested non-invasive markers, which included hyaluronic acid, type IV collagen 7S, aspartate aminotransferase-to-platelet ratio index, and fibrosis index based on four factors, according to receiver operating characteristic curve analysis.
CONCLUSION: Based on this histologically proven data, ATX represents a novel non-invasive biomarker for liver fibrosis in HBV-infected patients.
© 2017 The Japan Society of Hepatology.

Entities:  

Keywords:  autotaxin; chronic hepatitis B; liver cirrhosis; liver fibrosis

Year:  2017        PMID: 29114991     DOI: 10.1111/hepr.12997

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  10 in total

Review 1.  Skin Changes in Cirrhosis.

Authors:  Adhyatm Bhandari; Rahul Mahajan
Journal:  J Clin Exp Hepatol       Date:  2021-12-28

2.  Clinical impact of normal alanine aminotransferase on direct-acting antiviral outcome in patients with chronic hepatitis C virus infection.

Authors:  Satoru Joshita; Ayumi Sugiura; Takeji Umemura; Tomoo Yamazaki; Naoyuki Fujimori; Akihiro Matsumoto; Yoko Usami; Eiji Tanaka
Journal:  JGH Open       Date:  2019-12-23

3.  Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis.

Authors:  Satoru Joshita; Takeji Umemura; Yoko Usami; Yuki Yamashita; Gary L Norman; Ayumi Sugiura; Tomoo Yamazaki; Naoyuki Fujimori; Takefumi Kimura; Akihiro Matsumoto; Koji Igarashi; Kaname Yoshizawa; Masao Ota; Eiji Tanaka
Journal:  Sci Rep       Date:  2018-05-25       Impact factor: 4.379

4.  Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C.

Authors:  Kazuya Takemura; Etsuko Takizawa; Akihiro Tamori; Mika Nakamae; Hiroshi Kubota; Sawako Uchida-Kobayashi; Masaru Enomoto; Norifumi Kawada; Masayuki Hino
Journal:  Int J Mol Sci       Date:  2020-06-25       Impact factor: 5.923

Review 5.  Elevated Autotaxin and LPA Levels During Chronic Viral Hepatitis and Hepatocellular Carcinoma Associate with Systemic Immune Activation.

Authors:  Lenche Kostadinova; Carey L Shive; Donald D Anthony
Journal:  Cancers (Basel)       Date:  2019-11-25       Impact factor: 6.639

Review 6.  Cholestasis-Associated Pruritus and Its Pruritogens.

Authors:  Jacqueline A G M Langedijk; Ulrich H Beuers; Ronald P J Oude Elferink
Journal:  Front Med (Lausanne)       Date:  2021-03-09

7.  A type IV Autotaxin inhibitor ameliorates acute liver injury and nonalcoholic steatohepatitis.

Authors:  Anastassis Perrakis; Ruchi Bansal; Richell Booijink; Fernando Salgado-Polo; Craig Jamieson
Journal:  EMBO Mol Med       Date:  2022-07-14       Impact factor: 14.260

Review 8.  Coming of Age for Autotaxin and Lysophosphatidate Signaling: Clinical Applications for Preventing, Detecting and Targeting Tumor-Promoting Inflammation.

Authors:  Matthew G K Benesch; Iain T K MacIntyre; Todd P W McMullen; David N Brindley
Journal:  Cancers (Basel)       Date:  2018-03-15       Impact factor: 6.639

9.  Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C.

Authors:  Tomoo Yamazaki; Satoru Joshita; Takeji Umemura; Yoko Usami; Ayumi Sugiura; Naoyuki Fujimori; Takefumi Kimura; Akihiro Matsumoto; Koji Igarashi; Masao Ota; Eiji Tanaka
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

10.  Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis.

Authors:  Hatsue Fujino; Mio Tanaka; Michio Imamura; Kei Morio; Atsushi Ono; Takashi Nakahara; Eisuke Murakami; Tomokazu Kawaoka; Shoichi Takahashi; Daiki Miki; Masataka Tsuge; Akira Hiramatsu; Hiroshi Aikata; C Nelson Hayes; Kazuaki Chayama
Journal:  BMC Gastroenterol       Date:  2019-10-24       Impact factor: 3.067

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.